NovaBay Pharmaceuticals (NBY) 10-Q 14 Nov 17 2017 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 09, 2017
Document Information [Line Items]
Entity Registrant Name	NOVABAY PHARMACEUTICALS, INC.
Entity Central Index Key	1,389,545
Trading Symbol	nby
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		15,368,304
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
ASSETS
Cash and cash equivalents	$ 6,076	$ 9,512
Accounts receivable, net of allowance for doubtful accounts ($28 and $10 at September 30, 2017 and December 31, 2016, respectively)	2,230	2,120
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments of $139 and $196 at September 30, 2017 and December 31, 2016, respectively	599	873
Prepaid expenses and other current assets	1,033	1,966
Total current assets	9,938	14,471
Property and equipment, net	492	371
Other assets	626	539
TOTAL ASSETS	11,056	15,381
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable	356	455
Accrued liabilities	2,419	2,007
Deferred revenue	2,487	1,861
Total current liabilities	5,262	4,323
Deferred revenues – non-current	1,569	1,986
Deferred rent	286	327
Warrant liability	1,889	1,446
Other liabilities	218	198
Total liabilities	9,224	8,280
Stockholders’ equity:
Preferred stock: 5,000 shares authorized; none outstanding at September 30, 2017 and December 31, 2016	0	0
Common stock, $0.01 par value; 240,000 shares authorized; 15,361 and 15,269 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	154	153
Additional paid-in capital	113,545	110,619
Accumulated deficit	(111,867)	(103,671)
Total stockholders’ equity	1,832	7,101
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 11,056	$ 15,381

Consolidated Balance Sheets (C3

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Accounts receivable, allowance for doubtful accounts	$ 28	$ 10
Inventory, allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments	$ 139	$ 196
Preferred stock, shares authorized (in shares)	5,000	5,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	240,000	240,000
Common stock, shares issued (in shares)	15,361	15,269
Common stock, shares outstanding (in shares)	15,361	15,269

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Sales:
Product revenue, net	$ 4,080	$ 3,262	$ 11,868	$ 7,571
Other revenue, net	11	176	46	249
Total net sales	4,091	3,438	11,914	7,820
Product cost of goods sold	521	566	1,807	1,656
Gross profit	3,570	2,872	10,107	6,164
Research and development	132	4	264	1,215
Sales and marketing	3,296	2,663	10,412	8,660
General and administrative	2,311	2,266	7,134	5,241
Total operating expenses	5,739	4,933	17,810	15,116
Operating loss	(2,169)	(2,061)	(7,703)	(8,952)
Non-cash loss on changes in fair value of warrant liability	(281)	(1,671)	(501)	(2,480)
Other income (expense), net	(3)	4	(9)	69
Loss before provision for income taxes	(2,447)	(3,736)	(8,195)	(11,501)
Provision for income tax			(1)	(2)
Net loss and comprehensive loss	$ (2,447)	$ (3,736)	$ (8,196)	$ (11,503)
Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share)	$ (0.16)	$ (0.34)	$ (0.54)	$ (1.54)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (in shares)	15,324	10,913	15,306	7,481

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Operating activities:
Net loss	$ (8,196)	$ (11,503)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	54	98
Gain on disposal of property and equipment		(232)
Issuance of RSUs to employees		133
Issuance of RSUs to non-employees		20
Warrant modification		270
Stock option modification	243	58
Note receivable impairment		91
Leasehold improvements impairment		66
Non-cash loss on change in fair value of warrant liability	501	2,480
Changes in operating assets and liabilities:
Increase in accounts receivable	(109)	(1,544)
Decrease in inventory	273	261
Decrease (increase) in prepaid expenses and other current assets	943	(1,433)
Increase in other assets	(86)	(374)
Increase (decrease) in accounts payable and accrued liabilities	602	(1,923)
Increase in deferred rent	40	59
Increase in deferred revenue	6	818
Increase in other liabilities		198
Net cash used in operating activities	(3,344)	(11,441)
Investing activities:
Purchases of property and equipment	(228)	(78)
Net cash used in investing activities	(228)	(78)
Financing activities:
Proceeds from common stock issuances, net		13,648
Proceeds from exercise of warrants, net	38	6,571
Proceeds from exercise of stock options, net	129	0
Proceeds from stock options and restricted stock sold to cover taxes	17	15
Settlement of restricted stock for tax withholding	(48)	(15)
Proceeds from borrowings		1,365
Repayment of borrowings		(3,020)
Net cash provided by financing activities	136	18,564
Net change in cash and cash equivalents	(3,436)	7,045
Cash and cash equivalents, beginning of period	9,512	2,385
Cash and cash equivalents, end of period	6,076	9,430
Supplemental disclosure of non-cash information:
Stock issued to consultants for services, included in accounts payable and accrued liabilities	1	7
Property and equipment purchases, included in accounts payable and accrued liabilities	(52)	20
Equity transferred to warrant liability	58	1,594
Proceeds from stock options and restricted stock sold to cover taxes, in accounts payable and accrued liabilities	17
Exchange of equipment for services		279
Interest paid		51
Severance Paid in Restricted Stock Units to Non-employees [Member]
Supplemental disclosure of non-cash information:
Severance paid in RSU to non-employee	69
Employees and Directors [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense for options and stock issued	2,135	831
Nonemployees [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense for options and stock issued	$ 250	$ 185

Note 1 - Organization

Note 1 - Organization	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1. NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two ® ® ® ® ® The Company was incorporated under the laws of the State of California on January 19, 2000, no July 1, 2002, February 2007, June 2010, April 2016, four not four Effective December 18, 2015, 1 25 11 Liquidity Based primaril y on the funds available at September 30, 2017, October 2018. 2017 2017 may 1 2 3 one 4 may 1 3 not may

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying interim condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“GAAP”) and with the instructions for Form 10 X. not ’s Form 10 March 23, 2017. Reclassifications Prior period amounts in the accompanying consolidated balance sheets have been reclassified to conform to current period presentation. The reclassifications did not ’ equity. Prior period amounts in the accompanying consolidated statements of operations and comprehensive loss have also been reclassified to conform to current period presentation. The reclassifications did not Additionally, prior period amounts in the accompanying consolidated statements of cash flow have also been reclassified to conform to current period presentation. The reclassifications did not Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, DermaBay, Inc., as applicable. DermaBay, Inc. was dissolved by the Company in April 2016. Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization periods for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates. Unaudited Interim Financial Information The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not not Cash and Cash Equivalents The Company considers all highly-liquid instruments with a stated maturity of three roximates fair value. As of September 30, 2017, December 31, 2016, two Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits of cash and cash equivalents with two Deposits in these banks may not During the nine months ended September 30, 2017 2016, three During the three nine months ended September 30, 2017 2016, 10% Three Months Ended Nine Months Ended September 30, September 30, Major distribution or collaboration partner 2017 2016 2017 2016 Distributer A 25 % 21 % 24 % 18 % Distributer B 24 % 21 % 24 % 19 % Distributer C 23 % 16 % 21 % 15 % As of September 30, 2017 December 31, 2016, 10% Major distribution partner September 30, 2017 December 31, 2016 Distributer A 30 % 22 % Distributer B 22 % 24 % Distributer C 31 % 31 % The Company relies on two not third may not ’s needs with respect to timing, quantity or quality. Fair Value of Financial Assets and Liabilities Financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Our warrant liability is carried at fair value. The Company measures the fair value of financial assets and liabilities based on GAAP guidance, which defines fair value, establishes a framework for measuring fair value, and requires disclosures about fair value measurements. Under GAAP, fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is also established, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three may Level 1 – quoted prices in active markets for identical assets or liabilities; Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable; and Level 3 – inputs that are unobservable (for example, cash flow modeling inputs based on assumptions). Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identifies amounts due that are in dispute and it believes are unli kely to be collected. As of September 30, 2017 December 31, 2016, $28 $10 120 Inventory Inventory is comprised of ( 1 2 3 September 30, 2017 December 31, 2016, $139 $196 Inventory is stated at the lower of cost or estimated net realizable value determined by the first first Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three seven seven The costs of normal maintenance, repairs, and minor replacements are charged to operations when incurred. Impairment of Long-Lived Assets The Company accounts for long-lived assets in accordance with GAAP, which requires that companies consider whether events or changes in facts and circumstances, both internally and externally, may first 2016, no not not $91 velopment expense during the nine September 30, 2016. no nine September 30, 2017. not Comprehensive Income (Loss) Accounting Standards Codification (“ASC”) 220, Comprehensive Income Revenue Recognition The Company sells products through a limited number of distributors and via its webstore. The Company generally records product sales upon shipment to the final customer for its webstore sales and upon shipment from its distributor to the final customers for its major distribution partners. The Company recognizes product revenue when: (i) persuasive evidence that a sale arrangement exists, (ii) delivery has occurred and title has passed, (iii) the price is fixed or determinable, and (iv) collectability is reasonably assured. Revenue from sales transactions where the customer has the right to return the product is recognized at the time of sale only if: (i) the Company ’s price to the customer is substantially fixed or determinable at the date of sale, (ii) the customer has paid the Company, or the customer is obligated to pay the Company and the obligation is not not not Product Revenue Allowances Product revenue is recognized net of cash consideration paid to our customers and wholesalers, for services rendered by the wholesalers in accordance with the wholesalers’ agreements, and include a fixed rate per prescription shipped and monthly program management and data fees. These services are not Other product revenue allowances include certain prompt pay discounts and allowances offered to our customers, program rebates and chargebacks. These product revenue allowances are recognized as a reduction of revenue or as a selling expense at the later of the date at which the related revenue is recognized or the date at which the allowance is offered. Calculating certain of these items involves estimates and judgments based on sales or invoice data, contractual terms, utilization rates, new information regarding changes in these programs ’ regulations and guidelines that would impact the amount of the actual rebates or chargebacks. We review the adequacy of product revenue allowances on a quarterly basis. Amounts accrued for product revenue allowances are adjusted when trends or significant events indicate that adjustment is appropriate and to reflect actual experience. Other Revenue License and collaboration revenue is primarily generated through agreements with strategic partners for the development and commercialization of the Company ’s product candidates. The terms of the agreements typically include non-refundable upfront fees, funding of research and development activities, and payments based upon achievement of certain milestones and royalties on net product sales. In accordance with authoritative guidance, the Company analyzes its multiple element arrangements to determine whether the elements can be separated. The Company performs its analysis at the inception of the arrangement and as each product or service is delivered. If a product or service is not Cost of Goods Sold Cost of goods sold includes third Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include salaries and benefits for research and development personnel, costs associated with clinical trials managed by contract research organizations, and other costs associated with research, development and regulatory activities. Research and development costs may ’s research, clinical and development activities are often performed under agreements it enters with external service providers. The Company estimates and accrues the costs incurred under these agreements based on factors such as milestones achieved, patient enrollment, estimates of work performed, and historical data for similar arrangements. As actual costs are incurred, the Company adjusts its accruals. Historically, the Company’s accruals have been consistent with management’s estimates and no may Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss. Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of Accounting Standards Update (“ASU”) No. 2014 12, Compensation-Stock Compensation (Topic 718 12 Stock-based compensation arrangements with non-employees are recorded at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying equity instruments vest. Non-employee stock-based compensation charges are amortized over the vesting period on a straight-line basis. For stock options granted to non-employees, the fair value of the stock options is estimated using a Black-Scholes-Merton option pricing model. Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not Common Stock Warrant Liability For warrants that are issued or modified and there is a deemed possibility that the Company may ’s common stock eligible for purchase thereunder in the event that the Company subsequently issues equity instruments at a price lower than the exercise price of the warrants, the Company records the fair value of the issued or modified warrants as a liability at each balance sheet date and records changes in the estimated fair value as a non-cash gain or loss on the consolidated statements of operations and comprehensive loss. The fair values of these warrants have been determined using the Binomial Lattice (“Lattice”) valuation model, which provides for assumptions regarding volatility, call and put features and risk-free interest rates within the total period to maturity. These values are subject to a significant degree of the Company’s judgment. For additional information regarding the Company’s outstanding warrants, see Note 10 Net (Loss) per Share The Company computes net (loss) per share by presenting both basic and diluted (loss) per share (“EPS”). Basic EPS is computed by dividing net (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method, using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods since their effect would be anti-dilutive. During the three nine September 30, 2017 2016, no Three Months Ended Nine Months Ended September 30, September 30, (in thousands, except per share data) 2017 2016 2017 2016 Net loss $ (2,447 ) $ (3,736 ) $ (8,196 ) $ (11,503 ) Basic Shares 15,324 10,913 15,306 7,481 Add: shares issued upon assumed exercise of stock options and warrants — — — — Diluted shares 15,324 10,913 15,306 7,481 Basic and diluted net loss per share $ (0.16 ) $ (0.34 ) $ (0.54 ) $ (1.54 ) The following outstanding stock options and stock warrants were excluded from the diluted net loss per share computation, as their effect would have been anti-dilutive: As of September 30, (in thousands) 2017 2016 Period end stock options to purchase common stock 2,893 1,502 Period end common stock warrants 544 929 3,437 2,431 Recent Accounting Pronouncements In May 2014, FASB”) issued ASU No. 2014 09, Revenue from Contracts with Customers 606 August 2015 March, April, May December 2016, may 2014 09 December 15, 2017 , and permits companies to adopt the standard early. The Company plans to adopt the new standard effective January 1, 2018 , with a modified retrospective transition applying the new guidance to the most current period presented with the cumulative effect of changes reflected in the opening balance of retained earnings in the most current period presented. While the Company is still in the process of assessing the potential impact of this new standard on its consolidated financial statements, the Company has identified transactions which, under current guidance are recognized upon shipment from its distributor to the final customers for its major distribution partners will be recognized upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to. As a result, the Company will record contract liabilities for the invoiced amounts that are estimated to be subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, chargebacks, and product returns. The constraint on variable consideration for product returns will be a new estimation resulting from the earlier recognition under the new guidance. The Company has identified license and collaboration reve nue for which contract deliverables are currently accounted for as a combined unit of accounting because products or services are not . Under the new guidance, the Company has identified separate performance obligations that are capable of being distinct. As a result, the transaction price under these arrangements, including upfront fees and milestone payments, will be allocated differently to each performance obligation and may The Company identified the following performance obligations in its preliminary review of the license and collaboration agreements: ● Exclusive distribution rights in the product territory ● Regulatory submission and approval services ● Development services ● Sample supply, free of charge ● Incremental discounts and product supply prepayments representing a material right to the customer The Company has found that based upon the relative estimated selling prices of each performance obligation, the licenses typically makes up the majority of the transaction price allocation for each contract. Because the licenses have been classified under the new guidance as “right to use,” for which the customers right to the intellectual property is transferred at a point in time, under the new rules the revenue for each license will be considered recognized at contract inception. Based on these findings, the Company estimates a significant majority of the current deferred revenue balance related to its license and collaboration agreements will be allocated to performance obligations that were satisfied in periods prior to adoption and included in the cumulative adjustment to retained earnings upon adoption. The Company is still evaluating its major distribution agreements and its license and collaboration agreements and assessing the impact of adoption of the new standard to its consolidated financial statements. The Company will continue to monitor additional modifications, clarifications or interpretations undertaken by the FASB that may fourth 2017. In August 2014, 2014 15, Presentation of Financial Statements Going Concern (Subtopic 205 40 December 15, 2016 2014 15. 1 Liquidity. In July 2015, No. 2015 11, Inventory (Topic 330 No. 2015 11 first 2017. 2015 11 not In January 2016, 2016 01, Financial Instruments – Overall (Subtopic 825 10 Recognition and Measurement of Financial Assets and Financial Liabilities first 2018. In February 2016, 2016 02, Leases (Topic 842 Leases (Topic 840 2016 02 first 2019. In March 2016, 2016 09, Compensation – Stock Compensation (Topic 718 first 2017. 2016 09 not In August 2016, 2016 15, Classification of Certain Cash Receipts and Cash Payments (Topic 230 eight 2018. 2016 15 In November 2016, 2016 18, Statement of Cash Flows (Topic 230 2018. 2016 18 In July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 . 480 not December 15, 2018, 2017 11

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 3. The Company measures the fair value of financial assets and liabilities based on authoritative guidance which defines fair value, establishes a framework consisting of three about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company ’s warrant liability is classified within Level 3 The following table presents the Company ’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2017: Fair Value Measurements Using (in thousands) Balance at September 30, 2017 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash equivalents $ 101 $ 101 $ — $ — Restricted cash held as a certificate of deposit 324 324 — — Deposit held as a certificate of deposit 150 150 — — Total assets $ 575 $ 575 $ — $ — Liabilities Warrant liability $ 1,889 $ — $ — $ 1,889 Total liabilities $ 1,889 $ — $ — $ 1,889 The following table presents the Company ’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2016: Fair Value Measurements Using (in thousands) Balance at December 31, 2016 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash equivalents $ 100 $ 100 $ — $ — Restricted cash held as a certificate of deposit 324 324 — — Deposit held as a certificate of deposit 150 150 — — Total assets $ 574 $ 574 $ — $ — Liabilities Warrant liability $ 1,446 $ — $ — $ 1,446 Total liabilities $ 1,446 $ — $ — $ 1,446 As a result of the fair value adjustment of the warrant liability, the Company recorded non-cash expense of $281 three September 30, 2017, nine September 30, 2017, $501 10 (in thousands) Warrant liability Fair value of warrant liability at December 31, 2016 $ 1,446 Increase in fair value at March 31, 2017 235 Fair value of warrant liability at March 31, 2017 1,681 Decrease in fair value at June 30, 2017 (15 ) Fair market value of warrants transferred to equity upon exercise (58 ) Fair value of warrant liability at June 30, 2017 1,608 In crease in fair value at September 30, 2017 281 Fair va lue of warrant liability at September 30, 2017 $ 1,889

Note 4 - Prepaid Expenses and O

Note 4 - Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Prepaid Expenses and Other Current Assets [Text Block]	NOTE 4. Prepaid expenses and other current assets consisted of the following: (in thousands) September 30, 2017 December 31, 2016 Prepaid outsourced sales team $ — $ 606 Prepaid sales rebate 492 658 Prepaid rent — 120 Prepaid research and development services 100 123 Rent receivable 111 165 Prepaid insurance 67 31 Prepaid fleet leasing costs 75 — Other 188 263 Total prepaid expenses and other current assets $ 1,033 $ 1,966

Note 5 - Inventory

Note 5 - Inventory	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 5. Inventory consisted of the following: (in thousands) September 30, 2017 December 31, 2016 Raw materials and supplies $ 385 $ 514 Finished goods 353 555 Less allowance for excess and obsolete inventory and lower of cost or estimate net realizable value adjustments (139 ) (196 ) Total inventory, net $ 599 $ 873

Note 6 - Property and Equipment

Note 6 - Property and Equipment	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 6. Property and equipment consisted of the following: (in thousands) September 30, 2017 December 31, 2016 Office and laboratory equipment $ 24 $ 24 Furniture and fixtures 153 153 Computer equipment and software 339 170 Production equipment 105 105 Leasehold improvements 74 68 Total property and equipment, at cost 695 520 Less: accumulated depreciation and amortization (203 ) (149 ) Total property and equipment, net $ 492 $ 371 Depreciation and amortization expense was $18 $31 three September 30, 2017 2016, $54 $98 nine September 30, 2017 2016, In September 2016, $66 third 2016, three nine September 30, 2016. In September 2016, $232 third 2016, three nine September 30, 2016.

Note 7 - Accrued Liabilities

Note 7 - Accrued Liabilities	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 7. Accrued liabilities consisted of the following: (in thousands) September 30, 2017 December 31, 2016 Employee payroll and benefits $ 689 $ 763 Severance /retirement pay 347 250 Inventory 64 75 Legal 212 — Sales rebates 118 166 Outsourced sales team — 333 Distributer fees and discounts 230 206 Customer d eposit 540 — Other 219 214 Total accrued liabilities $ 2,419 $ 2,007

Note 8 - Related Party Notes Pa

Note 8 - Related Party Notes Payable	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Related Party Notes Payable [Text Block]	NOTE 8. Beginning on December 30, 2015, five 5 promissory notes (the “Notes”) payable to Mr. Mark Sieczkarek, the Gail J. Maderis Revocable Trust, Dr. T. Alex McPherson, Mr. Jian Ping Fu, and Pioneer Pharma (Singapore) Pte. Ltd. (“Pioneer Singapore”) $3.0 $199 $71 $20 $1.4 $1.4 two December 30, 2015 January 12, 2016. The proceeds from the Notes were used for general corporate purposes. Minimum March 31, 2016 June, September, December March no December 30, 2018, three 3 six 6% In connection with the Notes, China Kington agreed to act as collateral agent for the benefit of the Lenders, in accordance with the terms of a collateral agency and intercreditor agreement (the “Collateral Agency Agreement”), which was entered into on December 30, 2015 ) December 30, 2015. As consideration to China Kington for facilitating the Loan, the Company agreed to the following: ( 1 first two 2 $0 three 3 2 3 nine 9% 4 two 5 January 26, 2016 Upon closing the first $11.8 May 6, 2016 $2.5 Upon closing the second $11.8 August 1, 2016, $520 As of September 30, 2017, December 31, 2016,

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 9. Operating Leases Facility Lease s On August 24, 2016, 7,799 eleventh 1150 2000 94608 February 28, 2022, one five 5 no twelve 12 no nine 9 The Company still has a lease commitment for the laboratory facilities and office space at Suite 550, 5980 October 21, 2020. July 11, 2016, 16,465 September 8, 2016. October 21, 2020, ’s master lease for the EmeryStation premises is October 31, 2020), Rent expense, net for the above two $97 360 three September 30, 2017 2016, $293 $873 nine September 30, 2017 2016, The Company ’s monthly rent payments fluctuate under the various leases and sublease agreements. In accordance with GAAP, the Company recognizes rent expense on a straight-line basis. The Company records deferred rent and sublease future minimum payments receivable for the difference between the amounts paid and recorded as expense. Vehicle Fleet Leases During the nine months ended September 30, 2017, 54 36 September 30, 2017, 54 $14 $15 $3 36 Lease expense , net, for the vehicle fleet was approximately $28 zero three September 30, 2017 2016, $66 zero nine September 30, 2017 2016, Directors and Officers Indemnification As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving at the Company ’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may not September 30, 2017. In the normal course of business, the Company provides indemnification of varying scope under its agreements with other companies, typically its clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, it generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third not September 30, 2017. Legal Matters From time to time, the Company may December 19, 2016, ’s proxy statement filed with the SEC on April 18, 2016, May 17, 2016 ( “2016 2007 September 26, 2017, December 15, 2017. not

Note 10 - Warrant Liability

Note 10 - Warrant Liability	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	NOTE 10. In July 2011, 139,520 $33.25 January 1, 2012 July 5, 2016. 480, Distinguishing Liabilities from Equity 480 January 5, 2012, $66.50 ten not fifteen one third In October 2015, ’s securities purchase agreement dated March 3, 2015 ( “2015 twenty two March 3, 2016). October 2015 15 five 2015 “March 2015 June 29, 2011 ( “July 2011 March 2015 July 2011 $5.00 July 2011 March 6, 2020. July 2011 March 2015 $5.00 $5.00, In October 2015, 492,000 442,802 “October 2015 $5.00 “October 2015 60 October 2015 $5.00 $2.1 In February 2016, July 2011, March 2015 October 2015 $1.81 The key assumptions used to value the July 2011 September 30, 2017 December 31, 2016 As of Assumption September 30, 2017 December 31, 2016 Expected price volatility 103.00 % 102.00 % Expected term (in years) 2.43 3.18 Risk-free interest rate 1.54 % 1.51 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 3.51 $ 2.55 In March 2015, $15.00 $16.25 not ’s agreement to modify the terms of the March 2015 July 2011 October 2015, March 2015 March 2015 October 27, 2015 $1.8 October 27, 2015 October 27, 2015. The key assumptions used to value th e Short-Term Warrants as of September 30, 2017 December 31, 2016 As of Assumption September 30, 2017 December 31, 2016 Expected price volatility 103.00 % 102.00 % Expected term (in years) 2.43 3.18 Risk-free interest rate 1.54 % 1.51 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 3.05 $ 2.47 The key assumptions used to value the Long-Term Warrants as of September 30, 2017 December 31, 2016 As of Assumption September 30, 2017 December 31, 2016 Expected price volatility 103.00 % 102.00 % Expected term (in years) 2.43 3.18 Risk-free interest rate 1.54 % 1.51 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 3.51 $ 2.55 As noted above, the Company issued warrants in connection with the October 2015 October 2015 480, ’s potential obligation to cash-settle the warrants if specified fundamental transactions occur are deemed to be beyond the Company’s control. Due to this provision, ASC 480 October 27, 2015 $1.3 The key assumptions used to value the October 2015 September 30, 2017, December 31, 2016 As of Assumption September 30, 2017 December 31, 2016 Expected price volatility 99.00 % 96.00 % Expected term (in years) 3.08 3.83 Risk-free interest rate 1.63 % 1.66 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 3.62 $ 2.60 During the third 2016, 3,613,284 3,613,284 July 2011, March 2015 October 2015, $6.9 $1.6 $1.6 During the fourth 2016, 363,523 363,523 October 2011, November 2015 December 2015 $0.9 $0.5 $0.5 During the second 2017, 21,000 21,000 March 2015 $38 $58 $58 The details of the outstanding warrant liability as of September 30, 2017, Shares and dollars in thousands Shares Warrant Liability July 2011 Warrants 49 $ 174 Long-Term Warrants 96 337 Short-Term Warrants 115 349 October 2015 Warrants 284 1,029 544 $ 1,889

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity (Deficit)	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 11. ’ EQUITY (DEFICIT) Amendments to Articles of Incorporation —Reverse Stock Split Effective December 18, 2015, 1 25 ’s stockholders on December 11, 2015. Preferred Stock Under the Company ’s amended articles of incorporation, the Company is authorized to issue up to 5,000,000 may September 30, 2017 December 31, 2016, no Common Stock In February 2016, three 1,518,567 ’s common stock (the “Common Stock”) to accredited investors for a total of $2.8 first 696,590 $1.81, five 5% February 16, 2016, second 696,590 $1.91, February 16, 2016 no third 125,387 $1.91, February 16, 2016 no not may not China Kington Asset Management Co. Ltd. served as placement agent in exchange for a commission equal to six 6% $155 On April 4, 2016, 6,173,299 $0.01 “April 2016 3,086,651 $11.8 4 $1.91, ock, as reported on the NYSE American, is $4.00 five two first May 5, 2016, $7.8 second August 1, 2016, $4.0 4,079,058 April 2016 2,039,530 2,094,241 April 2016 1,047,121 China Kington Asset Management Co. Ltd. served as placement agent in exchange for a commission equal to six 6% $618 Also on April 4, 2016, ’s Brain Disease Foundation (the “Participating Purchasers”), pursuant to which the Company agreed to file as many registration statements with the SEC as may April 2016 April 2016 June 9, 2016 June 20, 2016 ( 333 211943 During the third 2016, $6.6 3,613,284 ’s warrants for 3,613,284 May 2016 August 2016. six 6% $338 During the fourth 2016, $0.9 363,523 ’s warrants for 363,523 six 6% $32 Stock Warrants In February 2016, July 2011, March 2015 October 2015 $1.81 In May 2016, 2,039,530 In August 2016, 1,047,121 Effective September 29, 2016, May 18, 2015, $19.50 $3.15 sixteen 16% ’s Common Stock on September 27, 2016. $270 The details of all outstanding warrants as of September 30, 2017, (in thousands, except for exercise price) Warrants Weighted- Average Exercise Price Warrants outstanding December 31, 2016 565 $ 1.81 Warrants granted — — Warrants exercised (21 ) 1.81 Warrants expired — — Warrants outstanding September 30, 2017 544 $ 1.81

Note 12 - Equity-based Compensa

Note 12 - Equity-based Compensation	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE 12. Equity Compensation Plans In October 2007, 2007 “2007 2007 40,000 2007 For the years from 2009 2012, 2007 40,000 4% ’s common stock outstanding on the last day of the preceding year; or (c) such lesser number as determined by the Board. Accordingly, an additional 40,000, 37,427, 37,207 2007 January 2012, 2011 2010, 2013, 40,000 2007 4% 32,646 59,157 2007 January 2014 2013, March 30, 2015, 82,461 2007 January 2016, 139,449 2007 2007 May 26, 2016, 2007 1,124,826 January 2017, 610,774 2007 2007 2007 2,318,486 March 15, 2017 ( 2007 Upon expiration of the 2007 2007 March 15, 2017 2007 may not 100% 10% ’s stock, then not 110% 2007 no ten four In March 2017, 2017 “2017 June 2, 2017, 2017 not ’s prior incentive plan, the 2007 2017 2,318,486 first January 1, 2018 January 1, 2027 four 4 2017 September 30, 2017, 1,486,028 2017 Under the terms of the 2017 may not 100% 10% ’s stock, then not 110% not ten not five ten four 2007 2017 Stock Option Summary The following table summarizes information about the Company ’s stock options outstanding as of September 30, 2017, nine (in thousands, except years and per share data) Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2016 1,489 $ 8.38 8.7 $ 702 Options granted 1,494 $ 2.99 Restricted stock units granted 39 $ — Options exercised (51 ) $ 2.50 Restricted stock units vested (31 ) $ — Options forfeited/cancelled (47 ) $ 27.45 Outstanding at September 30, 2017 2,893 $ 5.37 8.8 $ 4,564 Vested and expected to vest at September 30, 2017 2,832 $ 5.42 8.8 $ 4,459 Vested at September 30, 2017 1,236 $ 8.63 8.1 $ — Exercisable at September 30, 2017 1,236 $ 8.63 8.1 $ — The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company ’s common stock as quoted on the NYSE American as of September 30, 2017 51 three nine September 30, 2017 $129 $108 nine September 30, 2017. no three nine September 30, 2016. no three nine September 30, 2016. As of September 30, 2017, $2.5 ’s consolidated statements of operations and comprehensive loss over the remaining weighted average vesting period of 2.32 Stock Option Awards to Employees and Directors The Company grants options to purchase common stock to its employees and directors at prices equal to or greater than the market value of the stock on the dates the options are granted. The Company has estimated the value of stock option awards as of the date of grant by applying the Black-Scholes-Merton option pricing model using the single-option valuation approach. The application of this valuation model involves assumptions that are judgmental and subjective in nature. See Note 2 During the nine September 30, 2017 2016, 1,407,000 1,110,000 The weighted-average assumptions used in determining the value of options are as follows: Nine Months Ended September 30, Assumption 2017 2016 Expected price volatility 87.76 % 84.00 % Expected term (in years) 6.90 7.03 Risk-free interest rate 2.11 % 1.56 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 2.30 $ 2.03 Expected Price Volatility —This is a measure of the amount by which the common stock price has fluctuated or is expected to fluctuate. The computation of expected volatility was based on the historical volatility of the Company’s common stock and the common stock of comparable companies from a representative peer group selected based on industry and market capitalization data. Expected Term —This is the period of time over which the options granted are expected to remain outstanding. The expected life assumption is based on the Company’s historical data. Risk-Free Interest Rate —This is the U.S. Treasury rate for the week of the grant having a term approximating the expected life of the option. Dividend Yield —The Company has not Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate. During the nine September 30, 2017, not nine September 30, 2016, 64,000 For the three September 30, 2017 2016, $779 $610 For the nine September 30, 2017 2016, $2,379 $1,022 During the second third 2016, two May 6, 2016 August 24, 2016, three four ’s respective date of resignation. Options with an expiration date prior to the end of the exercise period maintained the same expiration date. In connection with the stock option modification, the Company recognized stock-based compensation expense of $58 In July 2017, December 31, 2017. three three third 2017, agrees to continue providing service through December 31, 2017, third fourth 2017. $243 three September 30, 2017. Stock-Based Awards to Non-Employee Consultants During the nine September 30, 2017 2016, 86,000 89,000 Nine Months Ended September 30, Assumption 2017 2016 Expected price volatility 87.41 % 88.00 % Expected term (in years) 10.00 9.99 Risk-free interest rate 2.27 % 1.61 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 2.40 $ 2.29 The Company granted restricted stock to non-employee consultants totaling 39,000 10,000 nine September 30, 2017 2016, For the three September 30, 2017 2016, $161 $100 nine September 30, 2017 2016, $250 $205 In November 2015, December 2016, 2016. December 31, 2015, December 2016. In January 2017, In March 2016, March 2016, December 31, 2015 March 2016. Summary of Stock-Based Compensation Expense A summary of the stock-based compensation expense included in the consolidated statement of operations and comprehensive loss for the options and common stock discussed above is as follows. The amounts that would have been charged to cost of goods sold are not Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2017 2016 2017 2016 Research and development $ 51 $ 63 $ 100 $ 142 Sales and Marketing 153 62 247 113 General and administrative 736 585 2,281 972 Total stock-based compensation expense $ 940 $ 710 $ 2,628 $ 1,227 Since the Company continues to operate at a net loss, it does not

Note 13 - License, Collaboratio

Note 13 - License, Collaboration and Distribution Agreements	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	NOTE 13. Virbac Agreement In April 2012, In April 2013, ’s proprietary compound, auriclosene (NVC- 422 may No evenue was recognized in the nine September 30, 2017 2016 The Company had deferred revenue balances of $246 September 30, 2017 December 31, 2016 NeutroPhase Distribution Agreements In January 2012, $312,500. $312,500 January 2013, first December 31, 2014, $625,000 In September 2012, two 1 2 one one Pursuant to the terms of the Distribution Agreement, Pioneer has the right to distribute NeutroPhase, upon a marketing approval from a Regulatory Authority, in certain territories in Asia (other than China). Upon execution of the Distribution Agreement, the Company received an upfront payment, which was recorded as deferred revenue. Pioneer is also obligated to make certain additional payments to the Company upon receipt of the marketing approval. The Distribution Agreement further provides that Pioneer is entitled to a cumulative purchase discount not $500,000 Pursuant to the Purchase Agreement, the Company also received $2.5 one one two 1 800,000 September 2012; 2 1,200,000 October 2012, $1.25 $3.5 purchased, and the fair value of the warrants based on the Black-Scholes Merton option pricing model. Because the aggregate fair value of the units on the dates of purchase exceeded the $2.5 $1 $600,000 In December 2013, two 1 1 Revenue has been recognized under these agreements as follows: Three Months Ended Nine Months Ended September 30, September 30, (in thousands) 2017 2016 2017 2016 Amortization of upfront technology access fee $ 6 $ 6 $ 19 $ 64 Product revenue - - 2 236 Total revenue recognized $ 6 $ 6 $ 21 $ 300 The Company had a deferred revenue balance of $1.0 September 30, 2017 December 31, 2016 On February 7, 2012, $750 Revenue has been recognized under this agreement as follows: Three Months Ended Nine Months Ended September 30, September 30, (in thousands) 2017 2016 2017 2016 Amortization of upfront technology access fee $ 4 $ 5 $ 25 $ 21 Product revenue 117 164 332 332 Total revenue recognized $ 121 $ 169 $ 357 $ 353 The Company had deferred revenue balances of $6 28 $653 September 30, 2017 December 31, 2016, On June 1, 2013, $200 Revenue has been recognized under this agreement as follows: Three Months Ended Nine Months Ended September 30, September 30, (in thousands) 2017 2016 2017 2016 Amortization of upfront technology access fee $ 1 $ - $ 2 $ - Product revenue 105 8 249 8 Total revenue recognized $ 106 $ 8 $ 251 $ 8 The Company had d eferred revenue balances of $192 $194 September 30, 2017 December 31, 2016, Avenova Distribution Agreements In November 2014, ’s commercialization strategy. McKesson makes Avenova widely available in local pharmacies and major retail chains across the U.S., such as Wal-Mart, Costco, CVS and Target. In January 2015, April 2015, December 2015, During the three September 30, 2017 2016, $3.5 $2.1 $9.3 $4.3 nine September 30, 2017 2016, The Company had a deferred revenue balance of $ 2.0 $1.9 September 30, 2017 December 31, 2016,

Note 14 - Employee Benefit Plan

Note 14 - Employee Benefit Plan	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	NOTE 14. The Company has a 401 not no nine September 30, 2017.

Note 15 - Related Party Transac

Note 15 - Related Party Transactions	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 15. Related Party Loans See Note 8, Maderis Revocable Trust, on behalf of Ms. Maderis, a Director of the Company; Dr. McPherson, a Director of the Company; and Pioneer Singapore and Mr. Fu, the Company’s two August 1, 2016. Related Party Financing See Note 11, ’ Equity (Deficit)” – “Common Stock” for a description of the February 2016 April 2016 two Related Party Revenue The Company recognized related party revenues from product sales and license and collaboration fees of $6 three September 30, 2017 2016, $21 $300 nine September 30, 2017 2016, no September 30, 2017 December 31, 2016. 13, Related Party Expenses The Company recognized related party commission fees of $0 $548 three September 30, 2017 2016, $0 $1,111 nine September 30, 2017 2016, ’s common stock. See Note 11,

Note 16 - Additional Disclosure

Note 16 - Additional Disclosures	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Additional Financial Information Disclosure [Text Block]	NOTE 16. On May 16, 2017, ’ equity as of March 31, 2017 1003 $6.0 five 12 May 16, 2018. June 29, 2017, September 14, 2017, not 1003 $4.0 three four not

Note 17 - Subsequent Events

Note 17 - Subsequent Events	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 17. On November 13, 2017, Purchase Agreement”) for the sale of an aggregate of 2,400,000 $0.01 $10.32 January 2018, 5,

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying interim condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“GAAP”) and with the instructions for Form 10 X. not ’s Form 10 March 23, 2017.
Reclassification, Policy [Policy Text Block]	Reclassifications Prior period amounts in the accompanying consolidated balance sheets have been reclassified to conform to current period presentation. The reclassifications did not ’ equity. Prior period amounts in the accompanying consolidated statements of operations and comprehensive loss have also been reclassified to conform to current period presentation. The reclassifications did not Additionally, prior period amounts in the accompanying consolidated statements of cash flow have also been reclassified to conform to current period presentation. The reclassifications did not
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, DermaBay, Inc., as applicable. DermaBay, Inc. was dissolved by the Company in April 2016.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization periods for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates.
Unaudited Interim Financial Information, Policy [Policy Text Block]	Unaudited Interim Financial Information The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly-liquid instruments with a stated maturity of three roximates fair value. As of September 30, 2017, December 31, 2016, two
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits of cash and cash equivalents with two Deposits in these banks may not During the nine months ended September 30, 2017 2016, three During the three nine months ended September 30, 2017 2016, 10% Three Months Ended Nine Months Ended September 30, September 30, Major distribution or collaboration partner 2017 2016 2017 2016 Distributer A 25 % 21 % 24 % 18 % Distributer B 24 % 21 % 24 % 19 % Distributer C 23 % 16 % 21 % 15 % As of September 30, 2017 December 31, 2016, 10% Major distribution partner September 30, 2017 December 31, 2016 Distributer A 30 % 22 % Distributer B 22 % 24 % Distributer C 31 % 31 % The Company relies on two not third may not ’s needs with respect to timing, quantity or quality.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value of Financial Assets and Liabilities Financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Our warrant liability is carried at fair value. The Company measures the fair value of financial assets and liabilities based on GAAP guidance, which defines fair value, establishes a framework for measuring fair value, and requires disclosures about fair value measurements. Under GAAP, fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is also established, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three may Level 1 – quoted prices in active markets for identical assets or liabilities; Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable; and Level 3 – inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identifies amounts due that are in dispute and it believes are unli kely to be collected. As of September 30, 2017 December 31, 2016, $28 $10 120
Inventory, Policy [Policy Text Block]	Inventory Inventory is comprised of ( 1 2 3 September 30, 2017 December 31, 2016, $139 $196 Inventory is stated at the lower of cost or estimated net realizable value determined by the first first
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three seven seven The costs of normal maintenance, repairs, and minor replacements are charged to operations when incurred.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company accounts for long-lived assets in accordance with GAAP, which requires that companies consider whether events or changes in facts and circumstances, both internally and externally, may first 2016, no not not $91 velopment expense during the nine September 30, 2016. no nine September 30, 2017. not
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) Accounting Standards Codification (“ASC”) 220, Comprehensive Income
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company sells products through a limited number of distributors and via its webstore. The Company generally records product sales upon shipment to the final customer for its webstore sales and upon shipment from its distributor to the final customers for its major distribution partners. The Company recognizes product revenue when: (i) persuasive evidence that a sale arrangement exists, (ii) delivery has occurred and title has passed, (iii) the price is fixed or determinable, and (iv) collectability is reasonably assured. Revenue from sales transactions where the customer has the right to return the product is recognized at the time of sale only if: (i) the Company ’s price to the customer is substantially fixed or determinable at the date of sale, (ii) the customer has paid the Company, or the customer is obligated to pay the Company and the obligation is not not not Product Revenue Allowances Product revenue is recognized net of cash consideration paid to our customers and wholesalers, for services rendered by the wholesalers in accordance with the wholesalers’ agreements, and include a fixed rate per prescription shipped and monthly program management and data fees. These services are not Other product revenue allowances include certain prompt pay discounts and allowances offered to our customers, program rebates and chargebacks. These product revenue allowances are recognized as a reduction of revenue or as a selling expense at the later of the date at which the related revenue is recognized or the date at which the allowance is offered. Calculating certain of these items involves estimates and judgments based on sales or invoice data, contractual terms, utilization rates, new information regarding changes in these programs ’ regulations and guidelines that would impact the amount of the actual rebates or chargebacks. We review the adequacy of product revenue allowances on a quarterly basis. Amounts accrued for product revenue allowances are adjusted when trends or significant events indicate that adjustment is appropriate and to reflect actual experience. Other Revenue License and collaboration revenue is primarily generated through agreements with strategic partners for the development and commercialization of the Company ’s product candidates. The terms of the agreements typically include non-refundable upfront fees, funding of research and development activities, and payments based upon achievement of certain milestones and royalties on net product sales. In accordance with authoritative guidance, the Company analyzes its multiple element arrangements to determine whether the elements can be separated. The Company performs its analysis at the inception of the arrangement and as each product or service is delivered. If a product or service is not
Cost of Sales, Policy [Policy Text Block]	Cost of Goods Sold Cost of goods sold includes third
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include salaries and benefits for research and development personnel, costs associated with clinical trials managed by contract research organizations, and other costs associated with research, development and regulatory activities. Research and development costs may ’s research, clinical and development activities are often performed under agreements it enters with external service providers. The Company estimates and accrues the costs incurred under these agreements based on factors such as milestones achieved, patient enrollment, estimates of work performed, and historical data for similar arrangements. As actual costs are incurred, the Company adjusts its accruals. Historically, the Company’s accruals have been consistent with management’s estimates and no may
Legal Costs, Policy [Policy Text Block]	Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of Accounting Standards Update (“ASU”) No. 2014 12, Compensation-Stock Compensation (Topic 718 12 Stock-based compensation arrangements with non-employees are recorded at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying equity instruments vest. Non-employee stock-based compensation charges are amortized over the vesting period on a straight-line basis. For stock options granted to non-employees, the fair value of the stock options is estimated using a Black-Scholes-Merton option pricing model.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not
Warrant Liabilities [Policy Text Block]	Common Stock Warrant Liability For warrants that are issued or modified and there is a deemed possibility that the Company may ’s common stock eligible for purchase thereunder in the event that the Company subsequently issues equity instruments at a price lower than the exercise price of the warrants, the Company records the fair value of the issued or modified warrants as a liability at each balance sheet date and records changes in the estimated fair value as a non-cash gain or loss on the consolidated statements of operations and comprehensive loss. The fair values of these warrants have been determined using the Binomial Lattice (“Lattice”) valuation model, which provides for assumptions regarding volatility, call and put features and risk-free interest rates within the total period to maturity. These values are subject to a significant degree of the Company’s judgment. For additional information regarding the Company’s outstanding warrants, see Note 10
Earnings Per Share, Policy [Policy Text Block]	Net (Loss) per Share The Company computes net (loss) per share by presenting both basic and diluted (loss) per share (“EPS”). Basic EPS is computed by dividing net (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method, using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods since their effect would be anti-dilutive. During the three nine September 30, 2017 2016, no Three Months Ended Nine Months Ended September 30, September 30, (in thousands, except per share data) 2017 2016 2017 2016 Net loss $ (2,447 ) $ (3,736 ) $ (8,196 ) $ (11,503 ) Basic Shares 15,324 10,913 15,306 7,481 Add: shares issued upon assumed exercise of stock options and warrants — — — — Diluted shares 15,324 10,913 15,306 7,481 Basic and diluted net loss per share $ (0.16 ) $ (0.34 ) $ (0.54 ) $ (1.54 ) The following outstanding stock options and stock warrants were excluded from the diluted net loss per share computation, as their effect would have been anti-dilutive: As of September 30, (in thousands) 2017 2016 Period end stock options to purchase common stock 2,893 1,502 Period end common stock warrants 544 929 3,437 2,431
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, FASB”) issued ASU No. 2014 09, Revenue from Contracts with Customers 606 August 2015 March, April, May December 2016, may 2014 09 December 15, 2017 , and permits companies to adopt the standard early. The Company plans to adopt the new standard effective January 1, 2018 , with a modified retrospective transition applying the new guidance to the most current period presented with the cumulative effect of changes reflected in the opening balance of retained earnings in the most current period presented. While the Company is still in the process of assessing the potential impact of this new standard on its consolidated financial statements, the Company has identified transactions which, under current guidance are recognized upon shipment from its distributor to the final customers for its major distribution partners will be recognized upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to. As a result, the Company will record contract liabilities for the invoiced amounts that are estimated to be subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, chargebacks, and product returns. The constraint on variable consideration for product returns will be a new estimation resulting from the earlier recognition under the new guidance. The Company has identified license and collaboration reve nue for which contract deliverables are currently accounted for as a combined unit of accounting because products or services are not . Under the new guidance, the Company has identified separate performance obligations that are capable of being distinct. As a result, the transaction price under these arrangements, including upfront fees and milestone payments, will be allocated differently to each performance obligation and may The Company identified the following performance obligations in its preliminary review of the license and collaboration agreements: ● Exclusive distribution rights in the product territory ● Regulatory submission and approval services ● Development services ● Sample supply, free of charge ● Incremental discounts and product supply prepayments representing a material right to the customer The Company has found that based upon the relative estimated selling prices of each performance obligation, the licenses typically makes up the majority of the transaction price allocation for each contract. Because the licenses have been classified under the new guidance as “right to use,” for which the customers right to the intellectual property is transferred at a point in time, under the new rules the revenue for each license will be considered recognized at contract inception. Based on these findings, the Company estimates a significant majority of the current deferred revenue balance related to its license and collaboration agreements will be allocated to performance obligations that were satisfied in periods prior to adoption and included in the cumulative adjustment to retained earnings upon adoption. The Company is still evaluating its major distribution agreements and its license and collaboration agreements and assessing the impact of adoption of the new standard to its consolidated financial statements. The Company will continue to monitor additional modifications, clarifications or interpretations undertaken by the FASB that may fourth 2017. In August 2014, 2014 15, Presentation of Financial Statements Going Concern (Subtopic 205 40 December 15, 2016 2014 15. 1 Liquidity. In July 2015, No. 2015 11, Inventory (Topic 330 No. 2015 11 first 2017. 2015 11 not In January 2016, 2016 01, Financial Instruments – Overall (Subtopic 825 10 Recognition and Measurement of Financial Assets and Financial Liabilities first 2018. In February 2016, 2016 02, Leases (Topic 842 Leases (Topic 840 2016 02 first 2019. In March 2016, 2016 09, Compensation – Stock Compensation (Topic 718 first 2017. 2016 09 not In August 2016, 2016 15, Classification of Certain Cash Receipts and Cash Payments (Topic 230 eight 2018. 2016 15 In November 2016, 2016 18, Statement of Cash Flows (Topic 230 2018. 2016 18 In July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 . 480 not December 15, 2018, 2017 11

Note 2 - Summary of Significa24

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, Major distribution or collaboration partner 2017 2016 2017 2016 Distributer A 25 % 21 % 24 % 18 % Distributer B 24 % 21 % 24 % 19 % Distributer C 23 % 16 % 21 % 15 % Major distribution partner September 30, 2017 December 31, 2016 Distributer A 30 % 22 % Distributer B 22 % 24 % Distributer C 31 % 31 %
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, (in thousands, except per share data) 2017 2016 2017 2016 Net loss $ (2,447 ) $ (3,736 ) $ (8,196 ) $ (11,503 ) Basic Shares 15,324 10,913 15,306 7,481 Add: shares issued upon assumed exercise of stock options and warrants — — — — Diluted shares 15,324 10,913 15,306 7,481 Basic and diluted net loss per share $ (0.16 ) $ (0.34 ) $ (0.54 ) $ (1.54 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of September 30, (in thousands) 2017 2016 Period end stock options to purchase common stock 2,893 1,502 Period end common stock warrants 544 929 3,437 2,431

Note 3 - Fair Value Measureme25

Note 3 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements Using (in thousands) Balance at September 30, 2017 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash equivalents $ 101 $ 101 $ — $ — Restricted cash held as a certificate of deposit 324 324 — — Deposit held as a certificate of deposit 150 150 — — Total assets $ 575 $ 575 $ — $ — Liabilities Warrant liability $ 1,889 $ — $ — $ 1,889 Total liabilities $ 1,889 $ — $ — $ 1,889 Fair Value Measurements Using (in thousands) Balance at December 31, 2016 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash equivalents $ 100 $ 100 $ — $ — Restricted cash held as a certificate of deposit 324 324 — — Deposit held as a certificate of deposit 150 150 — — Total assets $ 574 $ 574 $ — $ — Liabilities Warrant liability $ 1,446 $ — $ — $ 1,446 Total liabilities $ 1,446 $ — $ — $ 1,446
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	(in thousands) Warrant liability Fair value of warrant liability at December 31, 2016 $ 1,446 Increase in fair value at March 31, 2017 235 Fair value of warrant liability at March 31, 2017 1,681 Decrease in fair value at June 30, 2017 (15 ) Fair market value of warrants transferred to equity upon exercise (58 ) Fair value of warrant liability at June 30, 2017 1,608 In crease in fair value at September 30, 2017 281 Fair va lue of warrant liability at September 30, 2017 $ 1,889

Note 4 - Prepaid Expenses and26

Note 4 - Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	(in thousands) September 30, 2017 December 31, 2016 Prepaid outsourced sales team $ — $ 606 Prepaid sales rebate 492 658 Prepaid rent — 120 Prepaid research and development services 100 123 Rent receivable 111 165 Prepaid insurance 67 31 Prepaid fleet leasing costs 75 — Other 188 263 Total prepaid expenses and other current assets $ 1,033 $ 1,966

Note 5 - Inventory (Tables)

Note 5 - Inventory (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Inventory, Current [Table Text Block]	(in thousands) September 30, 2017 December 31, 2016 Raw materials and supplies $ 385 $ 514 Finished goods 353 555 Less allowance for excess and obsolete inventory and lower of cost or estimate net realizable value adjustments (139 ) (196 ) Total inventory, net $ 599 $ 873

Note 6 - Property and Equipme28

Note 6 - Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Property, Plant and Equipment [Table Text Block]	(in thousands) September 30, 2017 December 31, 2016 Office and laboratory equipment $ 24 $ 24 Furniture and fixtures 153 153 Computer equipment and software 339 170 Production equipment 105 105 Leasehold improvements 74 68 Total property and equipment, at cost 695 520 Less: accumulated depreciation and amortization (203 ) (149 ) Total property and equipment, net $ 492 $ 371

Note 7 - Accrued Liabilities (T

Note 7 - Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	(in thousands) September 30, 2017 December 31, 2016 Employee payroll and benefits $ 689 $ 763 Severance /retirement pay 347 250 Inventory 64 75 Legal 212 — Sales rebates 118 166 Outsourced sales team — 333 Distributer fees and discounts 230 206 Customer d eposit 540 — Other 219 214 Total accrued liabilities $ 2,419 $ 2,007

Note 10 - Warrant Liability (Ta

Note 10 - Warrant Liability (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Derivative Instruments [Table Text Block]	As of Assumption September 30, 2017 December 31, 2016 Expected price volatility 103.00 % 102.00 % Expected term (in years) 2.43 3.18 Risk-free interest rate 1.54 % 1.51 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 3.51 $ 2.55 As of Assumption September 30, 2017 December 31, 2016 Expected price volatility 103.00 % 102.00 % Expected term (in years) 2.43 3.18 Risk-free interest rate 1.54 % 1.51 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 3.05 $ 2.47 As of Assumption September 30, 2017 December 31, 2016 Expected price volatility 103.00 % 102.00 % Expected term (in years) 2.43 3.18 Risk-free interest rate 1.54 % 1.51 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 3.51 $ 2.55 As of Assumption September 30, 2017 December 31, 2016 Expected price volatility 99.00 % 96.00 % Expected term (in years) 3.08 3.83 Risk-free interest rate 1.63 % 1.66 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 3.62 $ 2.60
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	(in thousands, except for exercise price) Warrants Weighted- Average Exercise Price Warrants outstanding December 31, 2016 565 $ 1.81 Warrants granted — — Warrants exercised (21 ) 1.81 Warrants expired — — Warrants outstanding September 30, 2017 544 $ 1.81
July 2011, Long-term, Short-term, and October 2015 Warrants [Member]
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Shares and dollars in thousands Shares Warrant Liability July 2011 Warrants 49 $ 174 Long-Term Warrants 96 337 Short-Term Warrants 115 349 October 2015 Warrants 284 1,029 544 $ 1,889

Note 11 - Stockholders' Equit31

Note 11 - Stockholders' Equity (Deficit) (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	(in thousands, except for exercise price) Warrants Weighted- Average Exercise Price Warrants outstanding December 31, 2016 565 $ 1.81 Warrants granted — — Warrants exercised (21 ) 1.81 Warrants expired — — Warrants outstanding September 30, 2017 544 $ 1.81

Note 12 - Equity-based Compen32

Note 12 - Equity-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	(in thousands, except years and per share data) Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2016 1,489 $ 8.38 8.7 $ 702 Options granted 1,494 $ 2.99 Restricted stock units granted 39 $ — Options exercised (51 ) $ 2.50 Restricted stock units vested (31 ) $ — Options forfeited/cancelled (47 ) $ 27.45 Outstanding at September 30, 2017 2,893 $ 5.37 8.8 $ 4,564 Vested and expected to vest at September 30, 2017 2,832 $ 5.42 8.8 $ 4,459 Vested at September 30, 2017 1,236 $ 8.63 8.1 $ — Exercisable at September 30, 2017 1,236 $ 8.63 8.1 $ —
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2017 2016 2017 2016 Research and development $ 51 $ 63 $ 100 $ 142 Sales and Marketing 153 62 247 113 General and administrative 736 585 2,281 972 Total stock-based compensation expense $ 940 $ 710 $ 2,628 $ 1,227
Nonemployees [Member]
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Nine Months Ended September 30, Assumption 2017 2016 Expected price volatility 87.41 % 88.00 % Expected term (in years) 10.00 9.99 Risk-free interest rate 2.27 % 1.61 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 2.40 $ 2.29
Employees and Directors [Member]
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Nine Months Ended September 30, Assumption 2017 2016 Expected price volatility 87.76 % 84.00 % Expected term (in years) 6.90 7.03 Risk-free interest rate 2.11 % 1.56 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 2.30 $ 2.03

Note 13 - License, Collaborat33

Note 13 - License, Collaboration and Distribution Agreements (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, (in thousands) 2017 2016 2017 2016 Amortization of upfront technology access fee $ 6 $ 6 $ 19 $ 64 Product revenue - - 2 236 Total revenue recognized $ 6 $ 6 $ 21 $ 300 Three Months Ended Nine Months Ended September 30, September 30, (in thousands) 2017 2016 2017 2016 Amortization of upfront technology access fee $ 4 $ 5 $ 25 $ 21 Product revenue 117 164 332 332 Total revenue recognized $ 121 $ 169 $ 357 $ 353 Three Months Ended Nine Months Ended September 30, September 30, (in thousands) 2017 2016 2017 2016 Amortization of upfront technology access fee $ 1 $ - $ 2 $ - Product revenue 105 8 249 8 Total revenue recognized $ 106 $ 8 $ 251 $ 8

Note 1 - Organization (Details

Note 1 - Organization (Details Textual)	Dec. 18, 2015	Dec. 11, 2015	Sep. 30, 2017
Number of Operating Segments			4
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	25	25

Note 2 - Summary of Significa35

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Inventory Valuation Reserves	$ 139		$ 196
Impairment of Long-Lived Assets Held-for-use	$ 0
Research and Development Expense [Member]
Impairment of Long-Lived Assets Held-for-use		$ 91
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	5 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	7 years
Computer Equipment and Software [Member]
Property, Plant and Equipment, Useful Life	3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life	7 years
Allowance for Doubtful Accounts [Member]
Valuation Allowances and Reserves, Balance	$ 28		$ 10

Note 2 - Summary of Significa36

Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable From Major Distribution Partners and Customers (Details) - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Sales Revenue, Net [Member] | Distributor A [Member]
Concentration risk percentage	25.00%	21.00%	24.00%	18.00%
Sales Revenue, Net [Member] | Distributor B [Member]
Concentration risk percentage	24.00%	21.00%	24.00%	19.00%
Sales Revenue, Net [Member] | Distributor C [Member]
Concentration risk percentage	23.00%	16.00%	21.00%	15.00%
Accounts Receivable [Member] | Distributor A [Member]
Concentration risk percentage			30.00%		22.00%
Accounts Receivable [Member] | Distributor B [Member]
Concentration risk percentage			22.00%		24.00%
Accounts Receivable [Member] | Distributor C [Member]
Concentration risk percentage			31.00%		31.00%

Note 2 - Summary of Significa37

Note 2 - Summary of Significant Accounting Policies - Calculation of Basic and Diluted EPS (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Net loss	$ (2,447)	$ (3,736)	$ (8,196)	$ (11,503)
Basic Shares (in shares)	15,324	10,913	15,306	7,481
Diluted shares (in shares)	15,324	10,913	15,306	7,481
Basic and diluted net loss per share (in dollars per share)	$ (0.16)	$ (0.34)	$ (0.54)	$ (1.54)

Note 2 - Summary of Significa38

Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded from the Diluted Net Loss Per Share Computation (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Antidilutive securities (in shares)	3,437	2,431
Employee Stock Option [Member]
Antidilutive securities (in shares)	2,893	1,502
Warrant [Member]
Antidilutive securities (in shares)	544	929

Note 3 - Fair Value Measureme39

Note 3 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Fair Value Adjustment of Warrants	$ 281	$ 1,671	$ 501	$ 2,480

Note 3 - Fair Value Measureme40

Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Cash equivalents	$ 101	$ 100
Restricted cash held as a certificate of deposit	324	324
Deposit held as a certificate of deposit	150	150
Total assets	575	574
Warrant liability	1,889	1,446
Total liabilities	1,889	1,446
Fair Value, Inputs, Level 1 [Member]
Cash equivalents	101	100
Restricted cash held as a certificate of deposit	324	324
Deposit held as a certificate of deposit	150	150
Total assets	575	574
Warrant liability
Total liabilities
Fair Value, Inputs, Level 2 [Member]
Cash equivalents
Restricted cash held as a certificate of deposit
Deposit held as a certificate of deposit
Total assets
Warrant liability
Total liabilities
Fair Value, Inputs, Level 3 [Member]
Cash equivalents
Restricted cash held as a certificate of deposit
Deposit held as a certificate of deposit
Total assets
Warrant liability	1,889	1,446
Total liabilities	$ 1,889	$ 1,446

Note 3 - Fair Value Measureme41

Note 3 - Fair Value Measurements - Fair Value of Warrant Liability (Details) - Warrant Liability [Member] - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017
Fair value of warrant liability at beginning of period	$ 1,608	$ 1,681	$ 1,446
Increase (decrease) in fair value	281	(15)	235
Fair market value of warrants transferred to equity upon exercise		(58)
Fair value of warrant liability at end of period	$ 1,889	$ 1,608	$ 1,681

Note 4 - Prepaid Expenses and42

Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Prepaid outsourced sales team		$ 606
Prepaid sales rebate	492	658
Prepaid rent		120
Prepaid research and development services	100	123
Rent receivable	111	165
Prepaid insurance	67	31
Prepaid fleet leasing costs	75
Other	188	263
Total prepaid expenses and other current assets	$ 1,033	$ 1,966

Note 5 - Inventory - Summary of

Note 5 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Raw materials and supplies	$ 385	$ 514
Finished goods	353	555
Less allowance for excess and obsolete inventory and lower of cost or estimate net realizable value adjustments	(139)	(196)
Total inventory, net	$ 599	$ 873

Note 6 - Property and Equipme44

Note 6 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Depreciation, Depletion and Amortization	$ 18	$ 31	$ 54	$ 98
Impairment of Leasehold				66
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property				$ 232
General and Administrative Expense [Member] | Sublease Agreement [Member]
Impairment of Leasehold		66
Research and Development Expense [Member] | Laboratory Equipment [Member]
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property		$ 232

Note 6 - Property and Equipme45

Note 6 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Property and equipment, at cost	$ 695	$ 520
Less: accumulated depreciation and amortization	(203)	(149)
Total property and equipment, net	492	371
Equipment [Member]
Property and equipment, at cost	24	24
Furniture and Fixtures [Member]
Property and equipment, at cost	153	153
Computer Equipment and Software [Member]
Property and equipment, at cost	339	170
Production Equipment [Member]
Property and equipment, at cost	105	105
Leasehold Improvements [Member]
Property and equipment, at cost	$ 74	$ 68

Note 7 - Accrued Liabilities -

Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Employee payroll and benefits	$ 689	$ 763
Severance/retirement pay	347	250
Inventory	64	75
Legal	212
Sales rebates	118	166
Outsourced sales team		333
Distributer fees and discounts	230	206
Customer deposit	540
Other	219	214
Total accrued liabilities	$ 2,419	$ 2,007

Note 8 - Related Party Notes 47

Note 8 - Related Party Notes Payable (Details Textual) - USD ($)	Aug. 01, 2016	May 06, 2016	Jan. 12, 2016	Dec. 30, 2015	Sep. 30, 2017	Dec. 31, 2016
Proceeds from Issuance of Private Placement	$ 11,800,000	$ 11,800,000
Private Placement [Member]
Repayments of Related Party Debt	$ 520,000	$ 2,500,000
Notes [Member] | China Kingston [Member]
Loan Facilitation Consideration Lead Financings, Three Consecutive Months Cash Flow, Minimum				$ 0
Loan Facilitation Consideration Financing Provided By Board and Management on Next Financing, Percentage				9.00%
Loan Facilitation Consideration, Number of New Appointments to Board				2
Notes [Member] | Lenders [Member]
Proceeds from Related Party Debt				$ 3,000,000
Related Party Transaction, Rate				6.00%
Due to Related Parties					$ 0	$ 0
Promissory Note 1 [Member] | Board of Directors Chairman [Member]
Proceeds from Related Party Debt				$ 199,000
Promissory Note 2 [Member] | Director [Member]
Proceeds from Related Party Debt				71,000
Promissory Note 3 [Member] | Director [Member]
Proceeds from Related Party Debt				20,000
Promissory Note 4 [Member] | Pioneer Pharma Co. [Member]
Proceeds from Related Party Debt				$ 1,400,000
Promissory Note 5 [Member] | Mr. Fu [Member]
Proceeds from Related Party Debt			$ 1,400,000
Debt Instrument, Term			3 years

Note 9 - Commitments and Cont48

Note 9 - Commitments and Contingencies (Details Textual)	Aug. 24, 2016ft²	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Jul. 11, 2016ft²
Area of Property in Sublease Agreement | ft²						16,465
Operating Leases, Rent Expense		$ 97,000	$ 360,000	$ 293,000	$ 873,000
Master Fleet Lease Agreement [Member]
Number of Vehicles Leased				54
Lessee, Operating Lease, Term of Contract				3 years
Lease Agreement, Monthly Payment		14,000		$ 14,000
Lease Agreement, Management Fee Per Vehicle		15		15
Lease Agreement, Initial Payment Per Vehicle		3,000		3,000
Operating Leases, Rent Expense, Net		$ 28,000	$ 0	$ 66,000	$ 0
KBSIII Towers [Member]
Lessee Leasing Arrangements, Operating Leases, Square Feet of Property | ft²	7,799
Lessee, Operating Lease, Renewal Term	5 years
Lessee Leasing Arrangements, Operating Leases, Earliest Period Prior to Expiration of Current Term to Renew Lease	1 year
Lessee Leasing Arrangements, Operating Leases, Latest Period Prior to Expiration of Current Term to Renew Lease	270 days

Note 10 - Warrant Liability (De

Note 10 - Warrant Liability (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Aug. 01, 2016	May 05, 2016	Apr. 04, 2016	Feb. 16, 2016	Oct. 27, 2015	Oct. 27, 2015	Oct. 22, 2015	Jul. 31, 2011	Jun. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 29, 2016	Sep. 28, 2016	May 31, 2016	Feb. 29, 2016	Mar. 31, 2015	Jan. 05, 2012
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Warrants Issued								139,520
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 33.25		$ 1.81		$ 1.81		$ 3.15	$ 19.50
Minimum Common Stock Closing Bid Price Per Share																			$ 66.50
Stock Issued During Period, Shares, New Issues				1,518,567
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										363,523	3,613,284		3,613,284			2,039,530
Warrants and Rights Outstanding										$ 1,446		$ 1,889
Class of Warrant or Right, Exercised During Period										363,523	3,613,284	21,000
Proceeds from Warrant Exercises										$ 900	$ 6,600	$ 38	$ 6,571
Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.91
Warrant Expiration Term			4 years
Stock Issued During Period, Shares, New Issues	2,094,241	4,079,058	6,173,299
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,047,121	2,039,530	3,086,651
Underwriting Agreement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 5	$ 5
Warrant Expiration Term					5 years
Stock Issued During Period, Shares, New Issues						492,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					442,802	442,802
Proceeds from Issuance of Stock and Warrants					$ 2,100
Warrants and Rights Outstanding					1,300	$ 1,300
Mr. Fu [Member]
Stock Issued During Period, Shares, New Issues				696,590
Short-term Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights																		$ 15
Warrants and Rights Outstanding												349
Short-term Warrants [Member] | Private Placement [Member]
Warrant Expiration Term							1 year 90 days
Long-term Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights																		$ 16.25
Warrants and Rights Outstanding												$ 337
Long-term Warrants [Member] | Private Placement [Member]
Warrant Expiration Term							5 years
The 2011 and March 2015 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 5
Warrants to be Exercised at Lower Price Stock Price Trigger							5
Class of Warrant or Right Price Protection Provision Exchangeable Securities Exercise Price Trigger							$ 5
Warrants and Rights Outstanding					$ 1,800	$ 1,800
July 2011, March 2015, and October 2015 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										363,523	3,613,284		3,613,284
Class of Warrant or Right, Exercised During Period										363,523	3,613,284
Proceeds from Warrant Exercises										$ 900	$ 6,900
Warrant Liabilities, Fair Value Disclosure										500	1,600		$ 1,600
Fair Market Value of Warrants Transferred to Equity Upon Exercise										$ 500	$ 1,600
July 2011, March 2015, and October 2015 Warrants [Member] | Mr. Fu [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights																	$ 1.81
March 2015 Short-term and Long-term Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									21,000
Class of Warrant or Right, Exercised During Period									21,000
Proceeds from Warrant Exercises									$ 38
Warrant Liabilities, Fair Value Disclosure									58
Fair Market Value of Warrants Transferred to Equity Upon Exercise									$ 58

Note 10 - Warrant Liability - K

Note 10 - Warrant Liability - Key Assumptions Used to Value the Warrants (Details) - Warrant Fair Value [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
The 2011 Warrants [Member]
Expected price volatility	103.00%	102.00%
Expected term (Year)	2 years 156 days	3 years 65 days
Risk-free interest rate	1.54%	1.51%
Dividend yield	0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)	$ 3.51	$ 2.55
Short-term Warrants [Member]
Expected price volatility	103.00%	102.00%
Expected term (Year)	2 years 156 days	3 years 65 days
Risk-free interest rate	1.54%	1.51%
Dividend yield	0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)	$ 3.05	$ 2.47
Long-term Warrants [Member]
Expected price volatility	103.00%	102.00%
Expected term (Year)	2 years 156 days	3 years 65 days
Risk-free interest rate	1.54%	1.51%
Dividend yield	0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)	$ 3.51	$ 2.55
October 2015 Warrants [Member]
Expected price volatility	99.00%	96.00%
Expected term (Year)	3 years 29 days	3 years 302 days
Risk-free interest rate	1.63%	1.66%
Dividend yield	0.00%	0.00%
Weighted-average fair value of warrants (in dollars per share)	$ 3.62	$ 2.60

Note 10 - Warrant Liability - O

Note 10 - Warrant Liability - Outstanding Warrant Liability (Details) - USD ($) shares in Thousands, $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Shares (in shares)	544	565
Warrant liability	$ 1,889	$ 1,446
The 2011 Warrants [Member]
Shares (in shares)	49
Warrant liability	$ 174
Long-term Warrants [Member]
Shares (in shares)	96
Warrant liability	$ 337
Short-term Warrants [Member]
Shares (in shares)	115
Warrant liability	$ 349
October 2015 Warrants [Member]
Shares (in shares)	284
Warrant liability	$ 1,029
July 2011, Long-term, Short-term, and October 2015 Warrants [Member]
Shares (in shares)	544
Warrant liability	$ 1,889

Note 11 - Stockholders' Equit52

Note 11 - Stockholders' Equity (Deficit) (Details Textual) $ / shares in Units, $ in Thousands	Sep. 29, 2016USD ($)$ / shares	Aug. 01, 2016USD ($)shares	May 05, 2016USD ($)shares	Apr. 04, 2016USD ($)$ / sharesshares	Feb. 16, 2016USD ($)$ / sharesshares	Dec. 18, 2015	Dec. 11, 2015	Sep. 30, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Sep. 30, 2016USD ($)shares	Sep. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2016USD ($)shares	Sep. 28, 2016$ / shares	May 31, 2016shares	Feb. 29, 2016$ / shares	Jul. 31, 2011$ / shares
Preferred Stock, Shares Authorized								5,000,000	5,000,000		5,000,000
Preferred Stock, Shares Outstanding								0	0		0
Stock Issued During Period, Shares, New Issues					1,518,567
Stock Issued During Period, Value, New Issues | $					$ 2,800
Private Placement, Commission Percentage				6.00%	6.00%				6.00%	6.00%		6.00%
Common Stock, Par or Stated Value Per Share | $ / shares								$ 0.01	$ 0.01		$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									363,523	3,613,284		3,613,284		2,039,530
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 3.15							$ 1.81	$ 1.81		$ 1.81		$ 19.50			$ 33.25
Proceeds from Warrant Exercises | $									$ 900	$ 6,600	$ 38	$ 6,571
Class of Warrant or Right, Exercised During Period									363,523	3,613,284	21,000
Warrants Exercised, Commission Paid | $									$ 32	$ 338		338
Class of Warrant or Right, Exercise Price, Discount from Market Price	16.00%
Fair Value Adjustment of Warrants | $								$ 281		$ 1,671	$ 501	$ 2,480
General and Administrative Expense [Member]
Fair Value Adjustment of Warrants | $	$ 270
July 2011, March 2015, and October 2015 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									363,523	3,613,284		3,613,284
Proceeds from Warrant Exercises | $									$ 900	$ 6,900
Class of Warrant or Right, Exercised During Period									363,523	3,613,284
Mr. Fu [Member]
Stock Issued During Period, Shares, New Issues					696,590
Shares Issued, Price Per Share | $ / shares					$ 1.81
Mr. Fu [Member] | July 2011, March 2015, and October 2015 Warrants [Member]
Shares Issued, Price Per Share | $ / shares															$ 1.81
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares															$ 1.81
Pioneer Pharma Co. [Member]
Stock Issued During Period, Shares, New Issues					696,590
Shares Issued, Price Per Share | $ / shares					$ 1.91
Mr. Sieczkarek [Member]
Stock Issued During Period, Shares, New Issues					125,387
Shares Issued, Price Per Share | $ / shares					$ 1.91
Private Placement [Member]
Stock Issued During Period, Shares, New Issues		2,094,241	4,079,058	6,173,299
Common Stock, Par or Stated Value Per Share | $ / shares				$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,047,121	2,039,530	3,086,651
Sale of Stock, Consideration Received on Transaction | $		$ 4,000	$ 7,800	$ 11,800
Warrant Expiration Term				4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 1.91
Number of Sequential Trading Days				5 days
Private Placement [Member] | Minimum [Member]
Common Stock, Closing Price | $ / shares				$ 4
Private Placement [Member] | China Kington Asset Management Co. Ltd. [Member]
Payments of Stock Issuance Costs | $				$ 618	$ 155
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio						25	25

Note 11 - Stockholders' Equit53

Note 11 - Stockholders' Equity (Deficit) - Outstanding Warrants (Details) - $ / shares	3 Months Ended		9 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Sep. 30, 2017
Warrants outstanding (in shares)			565,000
Warrants outstanding, weighted average exercise price (in dollars per share)			$ 1.81
Warrants granted (in shares)
Warrants granted, weighted average exercise price (in dollars per share)
Warrants exercised (in shares)	(363,523)	(3,613,284)	(21,000)
Warrants exercised, weighted average exercise price (in dollars per share)			$ 1.81
Warrants expired (in shares)
Warrants expired, weighted average exercise price (in dollars per share)
Warrants outstanding (in shares)	565,000		544,000
Warrants outstanding, weighted average exercise price (in dollars per share)	$ 1.81		$ 1.81

Note 12 - Equity-based Compen54

Note 12 - Equity-based Compensation (Details Textual) - USD ($) $ in Thousands	Jan. 01, 2018	May 26, 2016	Mar. 30, 2015	Jan. 31, 2017	Jan. 31, 2016	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2012	Jan. 31, 2011	Jan. 31, 2010	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2016	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2017	Dec. 31, 2013	Dec. 31, 2012	Oct. 31, 2007
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period											51,000	0			51,000	0
Proceeds from Stock Options Exercised											$ 129	$ 0			$ 129	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value															$ 108
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross															1,494,000
Allocated Share-based Compensation Expense											940	710			$ 2,628	$ 1,227
Employees and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross															1,407,000	1,110,000
Allocated Share-based Compensation Expense											779	610			$ 2,379	$ 1,022
Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period															0	64,000
Nonemployees [Member]
Allocated Share-based Compensation Expense											$ 161	$ 100			$ 250	$ 205
Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued															86,000	89,000
Stock Issued During Period, Shares, Issued for Services															39,000	10,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period															4 years
Employee Stock Option [Member] | Mr. Radaelli and Mr. McPherson [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period													90 days	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost														$ 58
Employee Stock Option [Member] | Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period											90 days
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost											$ 243
Employee Stock Option [Member] | Chief Financial Officer [Member] | Scenario, Forecast [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	3 years
Employee Stock Options and RSUs [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized											$ 2,500				$ 2,500
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition															2 years 116 days
The 2007 Omnibus Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance																				40,000
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Annual Increase in Shares Authorized																			40,000
Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock																		4.00%	4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		1,124,826	82,461			32,646	59,157	40,000	37,427	37,207
Increase (Decrease) in Number of Shares Available for Grant				610,774	139,449
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		2,318,486
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum															10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period															4 years
The 2007 Omnibus Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent															100.00%
The 2007 Omnibus Incentive Plan [Member] | Minimum [Member] | Shareholder of More Than 10% [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent															110.00%
The 2007 Omnibus Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period															10 years
The 2017 Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock																	4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																	2,318,486
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant											1,486,028				1,486,028
The 2017 Omnibus Incentive Plan [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum															10.00%
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent															100.00%
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member] | Shareholder of More Than 10% [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent															110.00%
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period															10 years
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member] | Shareholder of More Than 10% [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period															5 years

Note 12 - Equity-based Compen55

Note 12 - Equity-based Compensation - Stock Options Outstanding (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Outstanding (in shares)			1,489,000
Outstanding, weighted-average exercise price (in dollars per share)			$ 8.38
Outstanding, weighted-average remaining contractual life (Year)			8 years 292 days		8 years 255 days
Outstanding, aggregate intrinsic value	$ 4,564		$ 4,564		$ 702
Options granted (in shares)			1,494,000
Options granted, weighted-average exercise price (in dollars per share)			$ 2.99
Options exercised (in shares)	(51,000)	0	(51,000)	0
Options exercised, weighted-average exercise price (in dollars per share)			$ 2.50
Options forfeited/cancelled (in shares)			(47,000)
Options forfeited/cancelled, weighted-average exercise price (in dollars per share)			$ 27.45
Outstanding (in shares)	2,893,000		2,893,000		1,489,000
Outstanding, weighted-average exercise price (in dollars per share)	$ 5.37		$ 5.37		$ 8.38
Vested and expected to vest (in shares)	2,832,000		2,832,000
Vested and expected to vest, weighted-average exercise price (in dollars per share)	$ 5.42		$ 5.42
Vested and expected to vest, weighted-average remaining contractual life (Year)			8 years 292 days
Vested and expected to vest, aggregate intrinsic value	$ 4,459		$ 4,459
Vested (in shares)	1,236,000		1,236,000
Vested, weighted-average exercise price (in dollars per share)	$ 8.63		$ 8.63
Vested, weighted-average remaining contractual life (Year)			8 years 36 days
Exercisable (in shares)	1,236,000		1,236,000
Exercisable, weighted-average exercise price (in dollars per share)	$ 8.63		$ 8.63
Exercisable, weighted-average remaining contractual life (Year)			8 years 36 days
Restricted Stock Units (RSUs) [Member]
Restricted stock units granted (in shares)			39,000
Restricted stock units granted, weighted-average exercise price (in dollars per share)
Restricted stock units vested (in shares)			(31,000)
Restricted stock units vested, weighted-average exercise price (in dollars per share)

Note 12 - Equity-based Compen56

Note 12 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) - Employees and Directors [Member] - $ / shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Expected price volatility	87.76%	84.00%
Expected term (Year)	6 years 328 days	7 years 10 days
Risk-free interest rate	2.11%	1.56%
Dividend yield	0.00%	0.00%
Weighted-average fair value of options granted during the period (in dollars per share)	$ 2.30	$ 2.03

Note 12 - Equity-based Compen57

Note 12 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Non-employees (Details) - Nonemployees [Member] - $ / shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Expected price volatility	87.41%	88.00%
Expected term (Year)	10 years	9 years 361 days
Risk-free interest rate	2.27%	1.61%
Dividend yield	0.00%	0.00%
Weighted-average fair value of options granted during the period (in dollars per share)	$ 2.40	$ 2.29

Note 12 - Equity-based Compen58

Note 12 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Stock-based compensation expense	$ 940	$ 710	$ 2,628	$ 1,227
Research and Development Expense [Member]
Stock-based compensation expense	51	63	100	142
Selling and Marketing Expense [Member]
Stock-based compensation expense	153	62	247	113
General and Administrative Expense [Member]
Stock-based compensation expense	$ 736	$ 585	$ 2,281	$ 972

Note 13 - License, Collaborat59

Note 13 - License, Collaboration and Distribution Agreements (Details Textual) - USD ($)	Jun. 01, 2013	Feb. 07, 2012	Jan. 31, 2013	Oct. 31, 2012	Sep. 30, 2012	Jan. 31, 2012	Oct. 31, 2012	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2016
Fees and Commissions, Other						$ 312,500
Contracts Revenue			$ 312,500										$ 625,000
Tranche One [Member]
Purchase Agreement Units					800,000
Purchase Agreement Unit Price Per Share					$ 1.25
Tranche Two [Member]
Purchase Agreement Units				1,200,000
Purchase Agreement Unit Price Per Share				$ 1.25
Purchase Unit Agreement Total Units Fair Value				$ 3,500,000
Reallocated from Deferred Revenue [Member]
Stockholders' Equity, Period Increase (Decrease)							$ 600,000
Restricted Stock Purchase [Member]
Contracts Revenue							2,500,000
Excess Fair Value Over Proceeds Received From Purchase							$ 1,000,000
Maximum [Member]
Sales Discounts, Goods												$ 500,000
Virbac [Member]
Deferred Revenue, Revenue Recognized										$ 0	$ 0
Deferred Revenue								$ 246,000		246,000				$ 246,000
Neutrophase [Member]
Deferred Revenue								1,000,000		1,000,000				1,000,000
Integrated Healing Technologies, LLC [Member]
Deferred Revenue								628,000		628,000				653,000
Commission Payment Received Upfront		$ 750,000
Principal Business Enterprise, Inc. [Member]
Deferred Revenue								192,000		192,000				194,000
Commission Payment Received Upfront	$ 200,000
Avenova Distribution Agreements [Member]
Deferred Revenue								2,000,000		2,000,000				$ 1,900,000
Contracts Revenue								$ 3,500,000	$ 2,100,000	$ 9,300,000	$ 4,300,000

Note 13 - License, Collaborat60

Note 13 - License, Collaboration and Distribution Agreements - Deferred Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Product revenue	$ 4,080	$ 3,262	$ 11,868	$ 7,571
Total revenue recognized	4,091	3,438	11,914	7,820
Pioneer Pharma Co. [Member] | Neutrophase [Member]
Amortization of upfront technology access fee	6	6	19	64
Product revenue			2	236
Total revenue recognized	6	6	21	300
Integrated Healing Technologies, LLC [Member] | Neutrophase [Member]
Amortization of upfront technology access fee	4	5	25	21
Product revenue	117	164	332	332
Total revenue recognized	121	169	357	353
Principal Business Enterprise, Inc. [Member] | Neutrophase [Member]
Amortization of upfront technology access fee	1		2
Product revenue	105	8	249	8
Total revenue recognized	$ 106	$ 8	$ 251	$ 8

Note 14 - Employee Benefit Pl61

Note 14 - Employee Benefit Plan (Details Textual) $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
The 401(k) Plan [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0

Note 15 - Related Party Trans62

Note 15 - Related Party Transactions (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Related-party Commission Fees [Member] | China Kingston [Member]
Related Party Transaction, Expenses from Transactions with Related Party	$ 0	$ 548,000	$ 0	$ 1,111,000
Amortization Revenue [Member] | Neutrophase [Member]
Other Income	$ 6,000	$ 6,000	$ 21,000	$ 300,000

Note 17 - Subsequent Events (De

Note 17 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Nov. 13, 2017	Aug. 01, 2016	May 05, 2016	Apr. 04, 2016	Feb. 16, 2016	Sep. 30, 2017	Dec. 31, 2016
Stock Issued During Period, Shares, New Issues					1,518,567
Common Stock, Par or Stated Value Per Share						$ 0.01	$ 0.01
Stock Issued During Period, Value, New Issues					$ 2,800
Private Placement [Member]
Stock Issued During Period, Shares, New Issues		2,094,241	4,079,058	6,173,299
Common Stock, Par or Stated Value Per Share				$ 0.01
Private Placement [Member] | One Accredited Investor [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues	2,400,000
Common Stock, Par or Stated Value Per Share	$ 0.01
Stock Issued During Period, Value, New Issues	$ 10,320